【导读】帕博西尼（Palbociclib）是一种CDK4/6抑制剂，在治疗HR+乳腺癌中发挥着至关重要的作用。然而，palbociclib的耐药性是一个值得进一步研究的重大问题。团队的研究发现，TMEM45A是palbociclib耐药性的潜在驱动因 ...

在华获批用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系BRCA突变（gBRCAm）、人表皮生长因子受体2（HER2）阴性早期高风险乳腺癌成人患者的 ...

In Jewish communities, conversations about genetic risks often focus on BRCA mutations and breast cancer. But this American ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The screening programme looks for mutations in the BRCA genes which push up a person’s risk of cancer. Everyone has BRCA1 and BRCA2 genes, but people who have changes in the gene are at higher ...

A global study revealed that young breast cancer patients with high risk BRCA mutations can have their risk of cancer recurrence reduced significantly by undergoing mastectomy and/or ovary removal, of ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard ...

"If one of my patients is already dealing with the difficult news of learning they're a BRCA mutation carrier, I don't ever want them to be surprised by having a child with an even more difficult ...

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

The programme offers free BRCA gene testing for people living in England aged 18 or over with at least one Jewish grandparent, regardless of faith, religious practice, or any other criteria. People of ...

Preclinical development of the lipid nanoparticle–based mRNA vaccine with multiple natural T cell epitopes for pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...